5WK0 Stock Overview A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Aligos Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Aligos Therapeutics Historical stock prices Current Share Price US$10.73 52 Week High US$25.50 52 Week Low US$7.15 Beta 2.12 1 Month Change 0% 3 Month Change -2.39% 1 Year Change -19.81% 3 Year Change -97.00% 5 Year Change n/a Change since IPO -97.76%
Recent News & Updates
Aligos Therapeutics, Inc. Reports Recent Business Progress Nov 07
Aligos Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERald Study of ALG-055009 for the Treatment of MASH Sep 19
Aligos Therapeutics Announces New Board Appointments Aug 09
Second quarter 2024 earnings released: EPS: US$0.032 (vs US$0.43 loss in 2Q 2023) Aug 07
Aligos Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31 See more updates
Aligos Therapeutics, Inc. Reports Recent Business Progress Nov 07
Aligos Therapeutics, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERald Study of ALG-055009 for the Treatment of MASH Sep 19
Aligos Therapeutics Announces New Board Appointments Aug 09
Second quarter 2024 earnings released: EPS: US$0.032 (vs US$0.43 loss in 2Q 2023) Aug 07
Aligos Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2A Herald Study for the Treatment of Mash May 23
First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023) May 08
Aligos Therapeutics, Inc., Annual General Meeting, Jun 27, 2024 May 01
Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects Apr 03
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies Mar 27
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects Mar 20
New major risk - Revenue and earnings growth Mar 14
Full year 2023 earnings released: US$1.36 loss per share (vs US$2.25 loss in FY 2022) Mar 13
Aligos Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024 Mar 06
Aligos Therapeutics, Inc. Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) Dec 08
Aligos Therapeutics, Inc. Announces Executive Changes Nov 17
Aligos Therapeutics, Inc. Presents Clinical and Nonclinical Data at the AASLD Liver Meeting®? 2023 Nov 15
Third quarter 2023 earnings released: US$0.41 loss per share (vs US$0.43 loss in 3Q 2022) Nov 04
New major risk - Share price stability Oct 28 Aligos Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Aligos Therapeutics, Inc. announced that it has received $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund Oct 26
Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors Oct 25 Aligos Therapeutics, Inc. announced that it expects to receive $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund and other investors Oct 24
Aligos Therapeutics Receives Non-Compliance Notice From Nasdaq Sep 08
Second quarter 2023 earnings released: US$0.43 loss per share (vs US$0.47 loss in 2Q 2022) Aug 06
Aligos Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
New major risk - Revenue and earnings growth Jul 07
Aligos Therapeutics Presents Data from Its Liver Disease Programs At the European Association for the Study of the Liver (Easl) Congress 2023 Jun 24
First quarter 2023 earnings released: US$0.54 loss per share (vs US$0.84 loss in 1Q 2022) May 07
Full year 2022 earnings released: US$2.25 loss per share (vs US$3.22 loss in FY 2021) Mar 11
Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009 Jan 06
Aligos Therapeutics Presents Clinical Data for Its Capsid Assembly Modulator, Alg-000184, At Aasld’S the Liver Meeting® 2022 Nov 05
Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.78 loss in 3Q 2021) Nov 04
Aligos Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Aligos Therapeutics Initiates Dosing in Healthy Volunteers with siRNA Drug Candidate ALG-125755 Oct 15
Aligos Therapeutics, Inc. Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud Sep 29
Second quarter 2022 earnings released: US$0.47 loss per share (vs US$0.79 loss in 2Q 2021) Aug 06
Aligos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 30
Aligos Therapeutics, Inc. Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating its Class II Capsid Assembly Modulator, ALG-000184 Jul 27 Aligos Therapeutics, Inc.(NasdaqGS:ALGS) dropped from Russell 2000 Growth Index
Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for Cam Drug Candidate ALG-000184, First Clinical Data for Nash Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs At the European Association for the Study of the Liver’s Digital International Liver Congress 2022 Jun 23
Aligos Therapeutics, Inc. to Participate in Metropolitan Antiviral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential Jun 07
Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs May 04
Aligos Therapeutics, Inc., Annual General Meeting, Jun 23, 2022 May 02
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development Apr 05
Aligos Therapeutics, Inc. Receives Notice of A Complaint Mar 31
Aligos Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 04
Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401) Jan 27
Aligos Therapeutics, Inc. Halting Further Development of STOPS™ Drug Candidate, ALG-010133 Jan 07
Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in A Phase 1 First-In-Human Study Dec 10
Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021 Dec 09 Aligos Therapeutics, Inc.(NasdaqGS:ALGS) dropped from Russell Microcap Value Index
Aligos Therapeutics to Present Preliminary Antiviral Activity of ALG-000184 in Chronic Hepatitis B (CHB) Subjects Jun 11 Shareholder Returns 5WK0 DE Biotechs DE Market 7D 0% -3.5% -2.0% 1Y -19.8% -14.7% 6.9%
See full shareholder returns
Return vs Market: 5WK0 underperformed the German Market which returned 9% over the past year.
Price Volatility Is 5WK0's price volatile compared to industry and market? 5WK0 volatility 5WK0 Average Weekly Movement n/a Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 5WK0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 5WK0's volatility change over the past year.
About the Company Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
Show more Aligos Therapeutics, Inc. Fundamentals Summary How do Aligos Therapeutics's earnings and revenue compare to its market cap? 5WK0 fundamental statistics Market cap €62.42m Earnings (TTM ) -€72.50m Revenue (TTM ) €5.65m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 5WK0 income statement (TTM ) Revenue US$6.00m Cost of Revenue US$73.04m Gross Profit -US$67.04m Other Expenses US$9.91m Earnings -US$76.95m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -20.73 Gross Margin -1,117.94% Net Profit Margin -1,283.19% Debt/Equity Ratio 0%
How did 5WK0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/13 22:56 End of Day Share Price 2024/08/16 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Aligos Therapeutics, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alethia Young Cantor Fitzgerald & Co. Antonio Arce H.C. Wainwright & Co. Michael Yee Jefferies LLC
Show 4 more analysts 